PT -期刊文章盟-拉斐尔施耐德盟Koroboshka Brand-Arzamendi盟——蒂莫西·雷诺Lim AU -杰弗里·格莱斯特盟梅兰妮Guenette盟Suradech Suthiphosuwan Jiwon哦TI - AU - Aditya Bharatha盟血浆神经丝光水平增加放射检查孤立综合症患者(p1 - 1. -虚拟)DP - 2022 2084年5月03 TA -神经病学PG - VI - 98 IP - 18补充4099 - //www.ez-admanager.com/content/98/18_Supplement/2084.short 4100 - //www.ez-admanager.com/content/98/18_Supplement/2084.首页full所以Neurology2022可能03;98 AB -目的:评估不同的等离子体光神经丝(pNfL)放射检查孤立综合症患者(pwRIS)与健康对照组(高碳钢)和关联pNfL水平与先进的磁共振成像(MRI)在pwRIS标记。背景:RIS指的是那些没有典型的症状,但女士大脑病变MRI特点与女士(pwm)。疾病修饰治疗的早期启动(DMT)可以提高pwm的预后,但目前没有明确如何管理pwRIS以证据为基础的指导方针。我们曾表明,绝大多数的pwRIS显示高比例的白质病变(wml)展示中央静脉(CVS)标志。之前的研究表明,血液NfL水平pwm与MRI的措施。我们假设pNfL水平增加一些pwRIS和与先进的核磁共振的措施。设计/方法:14 RIS主题和6高碳钢接受3 t大脑和颈部脊髓磁共振成像和测量水平pNfL HD-1 Simoa平台(Quanterix)。学生的t;和Mann-Whitney U-tests被用来评估差异RIS和高碳钢。结果:pwRIS有更高水平的pNfL与高碳钢(术中,0.05)。pwRIS超过20 CVS-positive病变或超过50个总wml pNfL水平明显高于与高碳钢。Conclusions: This pilot study is the first to demonstrate that pNfL levels are increased in pwRIS and correlate with the number of CVS-positive lesions and total number of WMLs. Although requiring prospective confirmation in a larger cohort, these findings suggest that pNfL may have prognostic value in identifying those pwRIS who are at high risk of developing MS. Prospective clinical validation is underway to confirm this hypothesis.Disclosure: Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb. Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Mrs. Brand-Arzamendi has nothing to disclose. Timothy R. Lim has nothing to disclose. Dr. Glaister has nothing to disclose. Melanie Guenette has nothing to disclose. Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb. Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. The institution of Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD-Serono. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Oh has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Oh has received research support from Biogen-Idec. The institution of Dr. Oh has received research support from EMD-Serono. The institution of Dr. Oh has received research support from Biogen-Idec.

map